Sector News

Categories

Borderless Insights

Image
Ditch Your CV Biases: Finding Your Next Leader Demands a Storyteller’s Curiosity
Image
Career 2.0: Mid-Career Transition for the Over-50 Executive
Image
How can we really achieve gender equity in the C-Suite?

Valeant closing in on $160-per-share Salix deal: Reuters

February 20, 2015
Life sciences
There are reportedly at least three horses in the race to buy Salix Pharmaceuticals, but according to Reuters’ sources, serial acquirer Valeant has the lead.
 
CEO J. Michael Pearson’s company is close to inking a deal for the North Carolina drugmaker at around $160 per share, the news service reports, and an agreement could come as early as next week.
 
But a couple other pharma players may have a mind to get in the way. Word has it that Shire is working with its own advisers on a potential offer, and Endo has also reportedly come calling multiple times.
 
A bidding war could potentially sour things for Valeant, which prides itself on its discipline. It’s that restraint that last November ended a months-long hostile pursuit of Allergan), with Pearson saying he “couldn’t justify” topping the $66 billion offer that white knight Actavis put forth.
 
And Shire, for one, has plenty of cash to throw around. CEO Flemming Ornskov has said multiple times that the Dublin drugmaker is looking for deals to help it reach its $10 billion 2020 sales goal, particularly in areas his company knows well. GI, Salix’s specialty, just so happens to be one such area.
 
For some of Salix’s investors, a sale will be a win no matter who nabs the company. Shareholders have been pushing for a buyout since Salix late last year acknowledged an inventory snafu that overstated sales and sent its CFO packing. After all, those issues may have already scuttled one deal: They cost it a tie-up with Allergan while it was looking to dodge Valeant, The Wall Street Journal said in November.
 
By Carly Helfand
 

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

Read more
December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

Read more
December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

Read more
More news

How can we help you?

We're easy to reach